CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.17 USD | -0.27% |
|
+3.47% | -12.39% |
| May. 14 | Transcript : Curis, Inc. - Special Call | |
| May. 14 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
Financials (USD)
| Sales 2024 * | 8.78M | Sales 2025 * | 8.8M | Capitalization | 65.84M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M | Net income 2025 * | -53M | EV / Sales 2024 * | 7.5 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.49 x |
| P/E ratio 2024 * |
-1.81
x | P/E ratio 2025 * |
-2.43
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -0.27% | ||
| 1 week | +3.47% | ||
| Current month | -27.23% | ||
| 1 month | -22.81% | ||
| 3 months | +14.33% | ||
| 6 months | -6.68% | ||
| Current year | -12.39% |
1 week
10.82
11.49
1 month
9.5016.99
Current year
8.2417.49
1 year
3.8018.00
3 years
3.80312.00
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
| Chief Tech/Sci/R&D Officer | - | 22-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 03-10-31 |
Martyn Greenacre
CHM | Chairman | 82 | 00-02-13 |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 11.17 | -0.27% | 33,473 |
| 24-05-24 | 11.2 | +0.54% | 8,163 |
| 24-05-23 | 11.14 | +2.96% | 9,295 |
| 24-05-22 | 10.82 | +0.23% | 23,878 |
| 24-05-21 | 10.8 | +2.61% | 14,833 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.17
USD
Average target price
78
USD
Spread / Average Target
+598.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.39% | 65.84M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +37.09% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- CRIS Stock
